Small molecule · developed by Aldeyra Therapeutics
Reproxalap is an ophthalmic solution administered as eye drops at 0.1% to 0.5% concentrations. It is studied in allergic conjunctivitis, non-infectious anterior uveitis and dry eye syndromes.
Summary written with AI from the sources listed at the end of this page.
| Trial | Phase | Condition | Status | Sponsor |
|---|---|---|---|---|
| NCT05234554 | Phase 3 | Allergic Conjunctivitis | Completed | ALDX |
| NCT03879863 | Phase 3 | Dry Eye | Completed | ALDX |
| NCT03445650 | Phase 3 | Sjogren-Larsson Syndrome | Completed | ALDX |
| NCT03494504 | Phase 3 | Allergic Conjunctivitis | Completed | ALDX |
| NCT03131154 | Phase 3 | Non-infectious Anterior Uveitis | Completed | ALDX |
| NCT03916042 | Phase 2 | Dry Eye | Completed | ALDX |
| NCT03404115 | Phase 2 | Dry Eye Syndrome | Completed | ALDX |
| NCT03162783 | Phase 2 | Dry Eye Syndromes | Completed | ALDX |
| NCT03012165 | Phase 2 | Conjunctivitis, Allergic | Completed | ALDX |
Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.
Allergic ConjunctivitisConjunctivitis, AllergicDry EyeDry Eye SyndromeNon-infectious Anterior UveitisSjogren-Larsson Syndrome
Updated Oct 11, 2026. Something wrong or missing? Report it on the ALDX page.
See ALDX's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.
ALDX catalysts and pipeline →